Glenstim PEG 6mg Injection

About

Pegfilgrastim is a pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF), designed to mitigate the risk of infection in cancer patients undergoing myelosuppressive chemotherapy. Its primary action involves stimulating the proliferation, differentiation, and activation of neutrophil precursors within the bone marrow, leading to a rapid increase in mature neutrophil counts. Neutrophils are essential components of the innate immune system, playing a critical role in combating bacterial infections. By effectively elevating neutrophil levels, pegfilgrastim significantly reduces the incidence and duration of febrile neutropenia, a severe and potentially life-threatening complication of chemotherapy. The pegylation process extends its half-life, allowing for a convenient single dose per chemotherapy cycle, thereby improving patient compliance and reducing the burden of frequent injections while maintaining robust hematopoietic support.

Uses

• Reduces incidence of febrile neutropenia in cancer patients.
• Used after myelosuppressive chemotherapy.
• Prevents chemotherapy-induced neutropenia.
• Supports bone marrow recovery.

Directions For Use

This injection is administered subcutaneously by a healthcare professional, typically once per chemotherapy cycle, at least 24 hours after chemotherapy.

Benefits

• Significantly reduces risk of febrile neutropenia.
• Allows for on-schedule chemotherapy cycles.
• Reduces hospitalizations due to infection.
• Convenient once-per-cycle dosing.
• Improves patient quality of life during chemotherapy.
• Supports immune system function.

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Headache
• Nausea
• Fatigue
• Injection site reactions
• Splenomegaly (enlarged spleen)
• Splenic rupture (rare but serious)
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)
• Allergic reactions
• Leukocytosis (high white blood cell count)

Safety Measures

• Alcohol - No specific interaction with alcohol is known. However, general health recommendations apply, and excessive alcohol may worsen fatigue or other general side effects.
• Pregnancy - Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown adverse effects.
• Breastfeeding - It is unknown if pegfilgrastim is excreted in human milk. Exercise caution when administering to a breastfeeding woman.
• Liver - No specific dose adjustment is typically required for patients with hepatic impairment.
• Kidney - No specific dose adjustment is typically required for patients with renal impairment.
• Lung - Rare cases of acute respiratory distress syndrome (ARDS) have been reported. Monitor patients for pulmonary symptoms such as cough, fever, and dyspnea.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.